One‐year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment

Abstract

In patients with T2DM and moderate or severe RI, vildagliptin added to ongoing antidiabetic therapy had a safety profile similar to placebo during 1-year observation. Furthermore, relative to placebo, a clinically significant decrease in A1C was maintained throughout 1-year treatment with vildagliptin.